Why the study?
Can cisplatin and etoposide chemotherapy induce myocardial infarction in patients with small cell carcinoma?
Can cisplatin and etoposide chemotherapy induce myocardial infarction in patients with small cell carcinoma?
This case highlights the potential for cisplatin and etoposide to induce acute coronary syndromes, emphasizing the importance of cardiac screening during chemotherapy.
May signal cisplatin-etoposide cardiotoxicity risk; hypothesis-generating and should not yet change practice.
Various drugs used to treat cancer cause hemodynamic/physiological changes in various organs of the body. Cardiotoxicity is one of the major side effects. Cardiotoxicity associated with chemotherapy can range from asymptomatic sub-clinical echocardiographic changes to life-threatening events like congestive heart failure or acute coronary syndrome. We present a case of cisplatin and etoposide-induced myocardial infarction (MI) during the second cycle of chemotherapy for bronchogenic carcinoma of the left lung (small cell carcinoma). The patient developed troponin positive NSTEMI and was managed conservatively. Here, the possible mechanism of action and the importance of cardiac screening while using cisplatin and etoposide are discussed.
No takes yet. Share an insight, caveat, or question.
Katta et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: